Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CBX-250 |
| Synonyms | |
| Therapy Description |
CBX-250 is a T-cell receptor mimetic-based bispecific T-cell engager targeting CD3 and an HLA-A2 restricted CG1 peptide, which potentially induces antitumor immune activity (Cancer Res (2024) 84 (6_Supplement): 1236). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CBX-250 | CBX250|CBX 250 | CD3 Antibody 119 | CBX-250 is a T-cell receptor mimetic-based bispecific T-cell engager targeting CD3 and an HLA-A2 restricted CG1 peptide, which potentially induces antitumor immune activity (Cancer Res (2024) 84 (6_Supplement): 1236). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06994676 | Phase I | CBX-250 | A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CROSSCHECK-001) | Recruiting | USA | 0 |